Cargando…

Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines

The recently emerged SARS-CoV-2 causing the ongoing COVID-19 pandemic is particularly virulent in the elderly while children are largely spared. Here, we explored the potential role of cross-reactive immunity acquired from pediatric vaccinations and exposure to common human pathogens in the protecti...

Descripción completa

Detalles Bibliográficos
Autor principal:	Reche, Pedro A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596387/ https://www.ncbi.nlm.nih.gov/pubmed/33178220 http://dx.doi.org/10.3389/fimmu.2020.586984

Ejemplares similares

Editorial: Innate immune responses to SARS-CoV-2 in infected and vaccinated individuals
por: Saksena, Nitin K., et al.
Publicado: (2023)

Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity
por: Lehmann, Alexander A., et al.
Publicado: (2021)

The impact of cross-reactive immunity on the emergence of SARS-CoV-2 variants
por: Thompson, Robin N., et al.
Publicado: (2023)

SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses
por: Schmidt, Katja G., et al.
Publicado: (2021)

Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
por: Grobben, Marloes, et al.
Publicado: (2021)

BCG Vaccine Derived Peptides Induce SARS-CoV-2 T Cell Cross-Reactivity
por: Eggenhuizen, Peter J., et al.
Publicado: (2021)

Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection
por: Liang, Yanwen, et al.
Publicado: (2020)

Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern
por: Schwarze, Mandy, et al.
Publicado: (2022)

Heterologous Immunity Between SARS-CoV-2 and Pathogenic Bacteria
por: Eggenhuizen, Peter J., et al.
Publicado: (2022)

HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients
por: Steiner, Sophie, et al.
Publicado: (2020)

SARS-CoV-2 Variants, Vaccines, and Host Immunity
por: Mistry, Priyal, et al.
Publicado: (2022)

The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune Deficiency
por: Quinti, Isabella, et al.
Publicado: (2022)

Pre-existing humoral immunity to low pathogenic human coronaviruses exhibits limited cross-reactive antibodies response against SARS-CoV-2 in children
por: Li, Nina, et al.
Publicado: (2022)

Engineering the common cold to be a live-attenuated SARS-CoV-2 vaccine
por: Kasman, Laura M.
Publicado: (2022)

SARS-CoV-2 epitope-specific T cells: Immunity response feature, TCR repertoire characteristics and cross-reactivity
por: Yang, Gang, et al.
Publicado: (2023)

Large-Scale Structure-Based Screening of Potential T Cell Cross-Reactivities Involving Peptide-Targets From BCG Vaccine and SARS-CoV-2
por: Tarabini, Renata Fioravanti, et al.
Publicado: (2022)

CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization
por: Haun, Brien K., et al.
Publicado: (2020)

Potential CD8+ T Cell Cross-Reactivity Against SARS-CoV-2 Conferred by Other Coronavirus Strains
por: Lee, Chloe H., et al.
Publicado: (2020)

Superior humoral immunity in vaccinated SARS-CoV-2 convalescence as compared to SARS-COV-2 infection or vaccination
por: Paniskaki, Krystallenia, et al.
Publicado: (2022)

Reaction of SARS-CoV-2 antibodies with other pathogens, vaccines, and food antigens
por: Vojdani, Aristo, et al.
Publicado: (2022)

Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2
por: Nguyen, Khue G., et al.
Publicado: (2022)

Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike
por: Crowley, Andrew R, et al.
Publicado: (2022)

Vaccine models predict rules for updating vaccines against evolving pathogens such as SARS-CoV-2 and influenza in the context of pre-existing immunity
por: Desikan, Rajat, et al.
Publicado: (2022)

Editorial: Mucosal immunity to HIV and SARS-CoV-2 infection and vaccination
por: Bomsel, Morgane, et al.
Publicado: (2023)

Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity
por: Scaglione, Antonella, et al.
Publicado: (2021)

Evaluating SARS-CoV-2 antibody reactivity to natural exposure and inactivated vaccination with peptide microarrays
por: Zheng, Peiyan, et al.
Publicado: (2023)

Potential Challenges for Coronavirus (SARS-CoV-2) Vaccines Under Trial
por: Usmani, Salman Sadullah, et al.
Publicado: (2020)

Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses
por: Bullen, Georgia, et al.
Publicado: (2021)

Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2?
por: Covián, Camila, et al.
Publicado: (2020)

The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines
por: Chan, Renee W. Y., et al.
Publicado: (2021)

SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments
por: Canedo-Marroquín, Gisela, et al.
Publicado: (2020)

Adaptive Immune Responses and Immunity to SARS-CoV-2
por: Primorac, Dragan, et al.
Publicado: (2022)

Combining different bacteria in vaccine formulations enhances the chance for antiviral cross-reactive immunity: a detailed in silico analysis for influenza A virus
por: Bodas-Pinedo, Andrés, et al.
Publicado: (2023)

IL-7 in SARS-CoV-2 Infection and as a Potential Vaccine Adjuvant
por: Bekele, Yonas, et al.
Publicado: (2021)

Antigenic Cross-Reactivity Between SARS-CoV-2 S1-RBD and Its Receptor ACE2
por: Lai, Yen-Chung, et al.
Publicado: (2022)

SARS-CoV-2 Infection and Guillain-Barré Syndrome: A Review on Potential Pathogenic Mechanisms
por: Shoraka, Shahrzad, et al.
Publicado: (2021)

Immunity to SARS-CoV-2: Lessons Learned
por: Fergie, Jaime, et al.
Publicado: (2021)

SARS-CoV-2 and the host-immune response
por: Maison, David P., et al.
Publicado: (2023)

Corrigendum: Combining different bacteria in vaccine formulations enhances the chance for antiviral cross-reactive immunity: a detailed in silico analysis for influenza A virus
por: Bodas-Pinedo, Andrés, et al.
Publicado: (2023)

Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination
por: Nogimori, Takuto, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lucf1qp7pddtqmscb82sjgrsj7